Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Gastrointestinal Stromal Tumors
Related studies linked through entity extraction aliases.
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
- Status
- COMPLETED
- Phase
- PHASE2
Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors
- Status
- COMPLETED
- Phase
- PHASE3
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
- Status
- UNKNOWN
- Phase
- PHASE2
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)
- Status
- COMPLETED
- Phase
- PHASE1
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
- Status
- COMPLETED
- Phase
- PHASE2
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
- Status
- COMPLETED
- Phase
- PHASE4
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
- Status
- COMPLETED
- Phase
- PHASE2
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
- Status
- COMPLETED
- Phase
- PHASE1